1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kane Biotech Inc.

Kane Biotech Inc.

KNBIF
Kane Biotech Inc.US flagOther OTC
0.02
USD
- -
- -
3.55MMarket Cap

Total Valuation

Kane Biotech Inc. carries a market capitalization of 3.55M, placing it among publicly traded companies globally. Its enterprise value stands at 7.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.55M
Enterprise Value7.22M

Share Statistics

Kane Biotech Inc. currently has 205.06M shares outstanding.

Shares Outstanding205.06M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 142.23, and the price-to-book ratio stands at -6.15.

PE RatioN/A
PS Ratio142.23
PB Ratio-6.15
P/TBV Ratio-3.90
P/FCF Ratio-2.27
P/OCF Ratio-2.20

Enterprise Valuation

EV / Sales186.48
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Kane Biotech Inc. maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -197.52, indicating conservative leverage, while an interest coverage ratio of -13.78 demonstrates limited ability to service its debt obligations.

Current Ratio0.61
Quick Ratio0.35
Debt / Equity-197.52
Debt / EBITDA-0.76
Interest Coverage-13.78

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-89.50
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.10

Taxes

Income Tax8,080.00
Effective Tax RateN/A

Stock Price Statistics

Kane Biotech Inc.'s stock has declined approximately -40.34483% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.02.

Beta (5Y)N/A
52-Week Price Change-40.34483%
50-Day Moving Average0.02
200-Day Moving Average0.02
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Kane Biotech Inc. generated 38,720.00 in revenue and converted that into -2.70M in net income, yielding earnings per share of -0.01. EBITDA reached -2.57M, while operating income came in at -2.68M.

Revenue38,720.00
Gross Profit-16.00
Operating Income-2.68M
Pretax Income-2.80M
Net Income-2.70M
EBITDA-2.57M
EBIT-2.68M
Earnings Per Share (EPS)-0.01

Balance Sheet

Kane Biotech Inc. holds 854,729.00 in cash and equivalents against 1.96M in total debt, resulting in a net debt position of 1.11M. Total book value stands at -993,863.00, with working capital of -988,701.00 providing operational flexibility.

Cash & Cash Equivalents854,729.00
Total Debt1.96M
Net Debt1.11M
Equity (Book Value)-993,863.00
Book Value Per Share0.00
Working Capital-988,701.00

Cash Flow

Kane Biotech Inc. produced -2.50M in operating cash flow over the past twelve months. After subtracting -72,634.00 in capital expenditures, free cash flow totaled -2.57M - equivalent to -0.01 per share.

Operating Cash Flow-2.50M
Capital Expenditures-72,634.00
Free Cash Flow-2.57M
FCF Per Share-0.01

Margins

Kane Biotech Inc. operates with a gross margin of -0.04, reflecting its pricing power and cost economics. The operating margin of -6,908.88 and net profit margin of -6,980.02 provide insight into operational efficiency.

Gross Margin-0.04
Operating Margin-6,908.88
Pretax Margin-7,238.09
Profit Margin-6,980.02
EBITDA Margin-6,649.04

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-28.68
FCF Yield-44.06

Stock Splits

Kane Biotech Inc.'s most recent stock split took place on March 13, 2017 with a 5:1 split ratio.

Last Split Date3/13/2017
Split Ratio5:1

Scores

Kane Biotech Inc. posts an Altman Z-Score of -37.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-37.58